Nipocalimab – the first and only neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus – is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with this disease while preserving immune function Results demonstrated...
Hence then, the article about johnson johnson late breaking results show nipocalimab significantly reduced systemic lupus erythematosus sle disease activity in a phase 2 study was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study )
Also on site :
- Carrboro Man Arrested, Charged With Sexual Exploitation of a Minor
- Trump berated Netanyahu? Analysts question US-Israel feud rumours
- Dunkin's New Limited-Edition Tumbler Is Guaranteed to Fly Off Shelves — How to Secure Yours